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Objectives
The aim of this study was to determine whether the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI)- or Cockcroft−Gault (CG)-based estimated glomerular filtration rates
(eGFRs) performs better in the cohort setting for predicting moderate/advanced chronic kidney
disease (CKD) or end-stage renal disease (ESRD).
Methods
A total of 9521 persons in the EuroSIDA study contributed 133 873 eGFRs. Poisson regression
was used to model the incidence of moderate and advanced CKD (confirmed eGFR < 60 and
< 30 mL/min/1.73 m2, respectively) or ESRD (fatal/nonfatal) using CG and CKD-EPI eGFRs.
Results
Of 133 873 eGFR values, the ratio of CG to CKD-EPI was ≥ 1.1 in 22 092 (16.5%) and the
difference between them (CG minus CKD-EPI) was ≥ 10 mL/min/1.73 m2 in 20 867 (15.6%).
Differences between CKD-EPI and CG were much greater when CG was not standardized for
body surface area (BSA). A total of 403 persons developed moderate CKD using CG [incidence
8.9/1000 person-years of follow-up (PYFU); 95% confidence interval (CI) 8.0–9.8] and 364
using CKD-EPI (incidence 7.3/1000 PYFU; 95% CI 6.5–8.0). CG-derived eGFRs were equal to
CKD-EPI-derived eGFRs at predicting ESRD (n = 36) and death (n = 565), as measured by the
Akaike information criterion. CG-based moderate and advanced CKDs were associated with
ESRD [adjusted incidence rate ratio (aIRR) 7.17; 95% CI 2.65–19.36 and aIRR 23.46; 95% CI
8.54–64.48, respectively], as were CKD-EPI-based moderate and advanced CKDs (aIRR 12.41;
95% CI 4.74–32.51 and aIRR 12.44; 95% CI 4.83–32.03, respectively).
Conclusions
Differences between eGFRs using CG adjusted for BSA or CKD-EPI were modest. In the absence
of a gold standard, the two formulae predicted clinical outcomes with equal precision and can
be used to estimate GFR in HIV-positive persons.
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Introduction
With increasing survival rates in HIV-positive persons, there is
an increase in the number of studies focusing on non-AIDS-
related conditions, including renal disease and markers of
renal function, such as glomerular filtration rate (GFR). Two
formulae are commonly used to estimate GFR; the Modifica-
tion of Diet in Renal Disease (MDRD) and Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equations.
The CKD-EPI equation was developed by the same group
as the MDRD equation, addressing some of the limitations
of the original MDRD equation [1,2]. A third formula,
Cockcroft−Gault (CG), estimates creatinine clearance [3].
These are based on serum creatinine measurements, which are
subject to considerable intrapersonal variation [4], which
increases at higher levels of serum creatinine [5]. The CG and
MDRD equations have been widely used in HIV-positive
persons, even though they were derived in HIV-negative
persons with other chronic illnesses, while the CKD-EPI
formula was derived in a less selected population [6]. MDRD
and, more recently, CKD-EPI have tended to be the formulae of
choice in the general population, with numerous studies
suggesting that CKD-EPI is superior to MDRD and CG [7–10].
Similar formula preferences exist for HIV-positive persons, as
MDRD and CKD-EPI do not require information on body
weight, while the CG formula does not require race.
Comparisons of the different eGFR formulae with a gold
standard in HIV-positive persons have, to date, been based
on small numbers and focused primarily on normal or
mildly impaired renal function [11–14], with contradictory
results. A larger study of 200 HIV-positive individuals stable
on combination antiretroviral therapy (cART) suggested that
CKD-EPI performed better than MDRD [15], while epidemio-
logical studies have mainly focused on a comparison of
CKD-EPI with MDRD, in the absence of a gold standard
[16,17]. Clearly, there is an urgent need for comparing the
different formulae to a gold standard to determine which has
greatest clinical relevance. Although less clinically relevant,
it is also relevant to compare formulae within cohort studies,
where no gold standard is available, to allow easier cross-
comparison of studies and interpretation of results.
The aims of these analyses were therefore to investigate
differences between the two most commonly used formu-
lae, CG and CKD-EPI, and to explore which best predicts
different levels of chronic kidney disease (CKD), end-stage
renal disease (ESRD) or deaths from kidney disease and
all-cause mortality.
Persons
The EuroSIDA study is a prospective, observational cohort
study of 18 722 HIV-positive persons in 108 centres across
33 European countries, plus Israel and Argentina. The
study has been described in detail previously [18]. In brief,
persons were enrolled in nine cohorts from May 1994
onwards. Information is collected on a standardized data
collection form every 6 months, including all CD4 counts
and viral loads measured since the last follow-up and
starting and stopping dates of all antiretrovirals. Dates of
diagnosis of all clinical AIDS-defining illnesses are rec-
orded using the 1993 clinical definition of AIDS from the
Centers for Disease Control and Prevention [19], as well as
all deaths, with cause of death determined by the Coding
Causes of Death in HIV (CoDe) protocol and by applying
a standardized algorithm [20,21]. Cardiovascular disease,
non-AIDS-defining malignancies, end-stage hepatic
encephalopathy, pancreatitis, and ESRD were included as
non-AIDS-defining events, as previously described [22].
All serum creatinine measurements obtained during
routine care have been collected since 1 January 2004.
To ensure correct person selection and to verify that
accurate data are supplied, members of the coordinating
office visit all centres to check the information provided
against case-notes for all persons with clinical events and
a randomly selected 10% of persons per year.
Statistical methods
Creatinine clearance (referred to as eGFR) was calculated
using CG and GFR using the CKD-EPI formula [2]. Evidence
on whether to adjust for body surface area (BSA) when
using CG is contradictory [23,24], and our main analyses
adjust for BSA [25], with some results presented unad-
justed. Weights were required to be measured within 1 year
of the serum creatinine measurement for CG eGFR to be
calculated. Serum creatinine measurements after 1 January
2004 were included, when routine collection of this data
began. The median date of last eGFR was March 2012. A
minimum of three eGFRs per person were required. Only
eGFRs where the CG was calculated at the same date as
CKD-EPI were included to ensure that eGFRs were being
compared at similar time-points. Baseline was defined as
the first time-point at which eGFR could be calculated with
both CG and CKD-EPI. A Bland−Altman plot was used to
summarize the differences between the two formulae [26].
eGFR groups were defined as normal (≥ 90 mL/min/
1.73 m2), mildly decreased (60–89 mL/min/1.73 m2), mod-
erately decreased (30–59 mL/min/1.73 m2) or severely
decreased (< 30 mL/min/1.73 m2). Models were adjusted for
gender, HIV transmission group, ethnic origin, region of
Europe, hepatitis B and C status, CD4 count, HIV viral load,
combination antiretroviral therapy (cART), prior AIDS
or non-AIDS diagnosis, diabetes, hypertension, anaemia,
smoking status and cardiovascular disease [22].
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Moderate CKD was defined as eGFR <60 mL/min/1.73 m2
and advanced CKD as eGFR <30 mL/min/1.73 m2 in at
least two consecutive measurements at least 3 months
apart among patients with an eGFR ≥ 60 mL/min/1.73 m2
or ≥ 30 mL/min/1.73 m2, respectively, with both formulae.
Incidence rates and the proportion progressing to moderate
and advanced CKD were calculated for both CG and CKD-
EPI, in patients with eGFR ≥ 60 or ≥ 30 at the first eGFR
measurement with both formulae. Among those who devel-
oped moderate CKD with either formula, logistic regression
was used to model the odds of not having moderate CKD
with both formulae (discordance), using forwards selection
with P < 0.1 as entry criterion. Models were adjusted for
the same factors as described above. Poisson regression,
with time-updated covariates, was used to identify the
predictors of moderate CKD using either formula. Patients
were followed from baseline until clinical event or last
eGFR. Models were adjusted as described above, adjusting
additionally for cumulative exposure to antiretrovirals
[27]. Poisson regression was also used to investigate the
relationship between eGFR and ESRD or death from renal
disease, or all cause mortality. ESRD was defined as hae-
modialysis or peritoneal dialysis lasting ≥ 1 month, or
a kidney transplant (further information at http://www
.cphiv.dk). Renal deaths occurred when renal disease was
the underlying cause of death, using the CoDe algorithm
[21]. Univariate and multivariate models were constructed
including current eGFRs, current eGFRs plus moderate and
advanced CKD, or moderate and advanced CKD for both
clinical endpoints. The fits of the models were compared
using the log-likelihood, the Akaike information criterion,
and the corrected Akaike information criteria to determine
whether CG or CKD-EPI was a better predictor of the
clinical endpoints [28].
All statistical analyses were performed using SAS version
9.3 (SAS Institute, Cary, NC).
Results
Of 11 865 persons with at least three eGFRs using CKD-EPI,
9521 (80.2%) also had corresponding eGFR measurements
using CG and were included in the analysis. Excluded
persons were less likely to be under follow-up in any
region compared with Southern Europe, to have hyper-
tension and to be antiretroviral experienced, and more
likely to be non-White, to be a former smoker and to have
a later baseline date. Characteristics of the 9521 included
persons are shown in Table 1. Patients were commonly
male (73.7%), White (87.2%) and homosexual (41.0%). At
baseline, 29.3% had a prior AIDS diagnosis, 6.5% a prior
non-AIDS-related event and 2.9% a prior cardiovascular
event. Median CD4 count was 438 cells/μL [interquartile
range (IQR) 293–620 cells/μL], median age was 41.9 years
(IQR 35.6–49.0 years) and median serum creatinine was
0.89 mg/dL (IQR 0.77–1.00 mg/dL). The number included
increased to 10 847 if CG was not standardized for BSA,
with similar characteristics to those shown in Table 1.
Table 1 Baseline characteristics of 10 487 persons with at least three
estimated glomerular filtration rates (eGFRs) using Cockcroft−Gault
(CG) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equations
n %
All 9521 100
Gender Male 7013 73.7
Female 2508 26.3
Race White 8301 87.2
Other 1220 12.8
Exposure group Homosexual 3906 41.0
IDU 1880 19.7
Heterosexual 2979 31.3
Other 756 7.9
Region of Europe South 2154 22.6
Central 2645 27.8
North 2159 22.7
East 2303 24.2
Argentina 260 2.7
Hepatitis B Negative 7691 80.8
Positive 582 6.1
Unknown 1248 13.1
Hepatitis C Negative 5984 62.9
Positive 2059 21.6
Unknown 1478 15.5
Prior AIDS diagnosis Yes 2794 29.3
Prior non-AIDS-related event* Yes 618 6.5
Prior CV event Yes 278 2.9
Diabetes No 8021 84.3
Yes 461 4.8
Unknown 1039 10.9
Hypertension No 5583 58.6
Yes 2806 29.5
Unknown 1132 11.9
Smoking Never 2747 28.8
Current 3006 31.6
Former 361 3.8
Unknown 3407 35.8
Anaemia No 5080 53.4
Yes 2018 21.2
Unknown 2423 25.4
ARV-naïve Yes 1275 13.4
Ever cART Yes 8000 84.0
On cART Yes 7807 82.0
Median
Interquartile
range
Baseline (month/year) 01/05 06/04–02/07
CD4 nadir (cells/μL) 160 60–273
CD4 (cells/μL) 438 293–620
Viral load (log10 copies/mL) 1.69 1.69–3.26
Age (years) 41.9 35.6–49.0
Serum creatinine (mg/dL) 0.89 0.77–1.00
ARV, antiretroviral; cART, combination antiretroviral therapy; CV, cardio-
vascular; IDU, injecting drug use.
Baseline was defined as the first time-point at which eGFR could be
calculated with both CG and CKD-EPI.
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There were 133 873 eGFRs with CG standardized for BSA
and CKD-EPI, a median of 13 (IQR 7–19) measurements
per person and a median time of 3.6 months (IQR 2.8–5.5
months) apart. Of the 133 873 measurements, 114 685
(85.7%) were in agreement; that is, they would be classified
as normal, mildly decreased, moderately decreased or
severely decreased with both formulae. Figure 1 shows a
Bland−Altman plot of the agreement between the two
formulae, which varied according to the mean eGFR. On
average, the CG eGFR was lower than the CKD-EPI eGFR;
the median difference between CKD-EPI and CG (CG minus
CKD-EPI) was −0.5 (IQR −6.0 to 5.8) mL/min/1.73 m2. In
those with severely decreased kidney function, estimated
with CG the difference was −2.3 (IQR –4.1 to −0.4) mL/min/
1.73 m2 and in those with a moderately decreased kidney
function it was 3.2 (IQR −0.6 to 7.4) mL/min/1.73 m2,
compared with 4.2 (IQR −0.6 to 9.0) mL/min/1.73 m2 and
−2.6 (IQR −10.2 to 3.1) mL/min/1.73 m2 in those with
mildly decreased or normal kidney function, respectively.
Comparing the eGFR groups (normal, mildly decreased,
moderately decreased and severely decreased) gave a kappa
of 0.75 [95% confidence interval (CI) 0.75–0.76]. The
overall correlation coefficient between CG and CKD-EPI (as
continuous variables) was 0.885. Correlations and kappas
were similar for those on and off antiretroviral therapy.
The agreement between CG and CKD-EPI was consider-
ably lower when CG was not standardized for BSA. Of
143 998 measurements (the higher number reflects the
fact that more measurements were available by not stand-
ardizing for BSA), 111 747 (77.6%) were in agreement using
the categories above. The CG eGFR was generally higher
than the CKD-EPI eGFR, with a median overall difference
between the CKD-EPI and CG eGFRs (CG minus CKD-EPI) of
−5.5 (IQR −18.5 to 5.6) mL/min. There was some variation
according to kidney function; in those with severely
decreased kidney function, according to CG the difference
was −1.9 (IQR –4.8 to −2.5) mL/min and in those with a
moderately decreased kidney function it was 7.0 (IQR −0.1 to
14.7 mL/min), compared with 5.3 (IQR −2.9 to 13.7) mL/min
and –12.8 (IQR –25.8 to −2.0) mL/min in those with mildly
decreased or normal kidney function, respectively. Compar-
ing the eGFR groups (normal, mildly decreased, moderately
decreased and severely decreased) gave a kappa of 0.60 (95%
CI 0.59–0.60). The overall correlation coefficient between
CG and CKD-EPI was also considerably lower at 0.754.
Moderate and advanced CKD (CG standardized
for BSA)
Of 9521 persons, 9121 (95.8%) had an eGFR ≥ 60 mL/min/
1.73 m2 at baseline with both CG and CKD-EPI, and 9497
(99.7%) had an eGFR ≥ 30 mL/min/1.73 m2 at baseline
with both formulae (Table 3). The highest incidence of,
and progression to, moderate CKD were seen with the CG
formula, with an incidence of 8.9 per 1000 person-years
of follow-up (PYFU; 95% CI 8.0–9.8), and 4.9% (95% CI
4.4–5.4) estimated to have developed moderate CKD by 6
years after baseline, using Kaplan−Meier estimation. Dif-
ferences in the incidence or Kaplan−Meier progression
rates of advanced CKD between the two formulae were
much smaller than those seen for moderate CKD (Table 2).
A total of 496 persons (5.4%) developed moderate CKD
using either CG or CKD-EPI; of these, 271 (54.6%) were
classified as having moderate CKD with both formulae (i.e.
concordant), 132 with CG but not CKD-EPI (26.6%) and 93
(18.8%) with CKD-EPI but not CG. The 271 persons classi-
fied as having CKD with both CKD-EPI and CG formulae
were compared with the 225 persons with CKD with either
CKD-EPI or CG but not both (Table 3). After adjustment,
hepatitis C virus (HCV)-positive persons were less likely
to be discordant [adjusted odds ratio (aOR) 0.56; 95% CI
0.35–0.90], as were those with unknown HIV exposure
(aOR 0.47; 95% CI 0.23–0.97). Persons of a non-White
ethnic origin were more likely be discordant (aOR 1.73;
95% CI 0.98–3.06), as were those with a later baseline date
(aOR 1.26 per year later; 95% CI 1.09–1.45). Of 271 who
developed CKD with one formula but not the other, 15.1%
were HCV-positive, 5.3% were in another HIV exposure
group and 14.2% were non-White participants, compared
with 23.6, 10.3 and 9.2%, respectively, of the 271 individ-
uals classified as having CKD with both formulae. There
were 49 persons (0.5%) who had advanced CKD with CG or
CKD-EPI; of these, 36 had advanced CKD with both for-
mulae (73.5%), nine (18.4%) had advanced CKD with CKD-
EPI but not CG, and four (8.2%) had advanced CKD with CG
Fig. 1 Bland−Altman plot of differences between estimated glomerular
filtration rates (eGFRs) calculated using Cockcroft−Gault (CG) and
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
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and not CKD-EPI. Small numbers precluded any additional
analyses.
In general, the same predictors were found for moderate
CKD regardless of whether it was defined using CG or
CKD-EPI (data not shown). The relationships between
cumulative exposure to antiretrovirals and moderate CKD
were similar using both the CG and CKD-EPI formulae.
Predictors of clinical events: comparison of CG
(standardized for BSA) and CKD-EPI formulae
There were 36 persons who developed ESRD or who died
from renal disease (incidence rate 0.7/1000 PYFU; 95% CI
0.5–0.9) and 565 deaths (incidence 10.8/1000 PYFU; 95%
CI 9.9–11.7) during prospective follow-up. CG-derived
eGFRs were equal to CKD-EPI-derived eGFRs at predicting
both ESRD and death, as measured by a lower Akaike
information criterion and log-likelihood, summarized
in Figure 2. After adjustment, CG-derived moderate and
advanced CKDs were associated with ESRD [adjusted inci-
dence rate ratio (aIRR) 7.17; 95% CI 2.65–19.36 and aIRR
23.46; 95% CI 8.54–64.48, respectively], as were CKD-EPI-
derived moderate and advanced CKDs (aIRR 12.41; 95%
CI 4.74–32.51 and aIRR 12.44; 95% CI 4.83–32.03, respec-
tively). CG-derived moderate CKD but not advanced CKD
was associated with all-cause mortality (aIRR 1.45; 95%
CI 1.11–1.90 and aIRR 1.52; 95% CI 0.87–2.67, respec-
tively), while CKD-EPI-derived moderate CKD was not
Table 2 Incidence and Kaplan−Meier (KM) estimates of moderate and advanced chronic kidney disease (CKD)
CG (standardized for BSA) CKD-EPI
Moderate CKD (n = 9121)
Baseline eGFR [median (IQR)] 98.9 (85.3–113.9) 101.0 (87.9–111.4)
eGFR > 90 mL/min/1.73 m2 [n (%)] 6056 (66.4) 6505 (71.3)
Events (%) 403 (4.4) 364 (4.0)
PYFU 45 326 50 147
Incidence/1000 PYFU (95% CI) 8.9 (8.0–9.8) 7.3 (6.5–8.0)
KM, 24 months (95% CI) 1.2 (1.0–1.4) 0.9 (0.7–1.1)
KM, 48 months (95% CI) 3.0 (2.6–3.4) 2.4 (2.1–2.7)
KM, 72 months (95% CI) 4.9 (4.4–5.4) 4.0 (3.5–4.5)
Advanced CKD (n = 9497)
Baseline eGFR [median (IQR)] 97.5 (83.7–113.1) 100.2 (86.0–111.0)
eGFR > 90 mL/min/1.73 m2 [n (%)] 6056 (63.8) 6510 (68.6)
Events (%) 40 (0.4) 45 (0.5)
PYFU 4105 53 055
Incidence/1000 PYFU (95% CI) 0.8 (0.6–1.1) 0.9 (0.6–1.0)
KM, 24 months (95% CI) 0.11 (0.03–0.16) 0.08 (0.02–0.14)
KM, 48 months (95% CI) 0.22 (0.11–0.32) 0.27 (0.16–0.38)
KM, 72 months (95% CI) 0.51 (0.32–0.69) 0.55 (0.37–0.72)
BSA, body surface area; CG, Cockcroft−Gault; CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated
glomerular filtration rate; IQR, interquartile range; PYFU, person-years of follow-up.
Moderate CKD was defined as eGFR < 60 mL/min/1.73 m2 and advanced CKD as eGFR <30 mL/min/1.73 m2 in at least two consecutive measurements at least
3 months apart.
A total of 9121 patients with eGFR > 60/mL/min/1.73 m3 at baseline with both formulae were included in estimates of moderate CKD; 9497 patients with
eGFR > 30 mL/min/1.73 m2 at baseline with both formulae were included in estimates of advanced CKD.
Table 3 Odds of discordance [chronic kidney disease (CKD) defined with Cockcroft−Gault (CG) but not Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) or vice versa] in classification of CKD
Univariate Multivariate
OR 95% CI P OR 95% CI P
Ethnicity White 1.00 – – 1.00 – –
Other 1.63 0.94–2.85 0.085 1.73 0.98–3.06 0.061
HCV antibody Negative/unknown 1.00 – – 1.00 – –
Positive 0.58 0.36–0.91 0.019 0.56 0.35–0.90 0.016
HIV exposure MSM/IDU/Het 1.00 – – 1.00 – –
Other 0.49 0.24–0.99 0.046 0.47 0.23–0.97 0.040
Diabetes No/unknown 1.00 – – 1.00 – –
Yes 0.67 0.38–1.19 0.17 0.63 0.35–1.13 0.12
Baseline date Per year later 1.23 1.07–1.42 0.0031 1.26 1.09–1.45 0.0020
CI, confidence interval; HCV, hepatitis C virus; Het, heterosexual; IDU, injecting drug user; MSM, men who have sex with men; OR, odds ratio.
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significantly associated with all-cause mortality, but
advanced CKD was (aIRR 1.12; 95% CI 0.84–1.50 and aIRR
2.08; 95% CI 1.22–3.57, respectively).
Discussion
This study of 133 873 eGFRs in 9521 HIV-positive persons
showed, in general, modest differences between eGFRs
calculated using the CG or CKD-EPI formula. eGFRs were
slightly higher with CKD-EPI than with CG. The incidence
of moderate CKD was higher using CG than CKD-EPI,
although similar HIV- and non-HIV-related risk factors
were found, while the incidence of advanced CKD was
similar and a rare event with either definition. CG-based
eGFRs performed as well as CKD-EPI-based eGFRs in pre-
dicting ESRD and all-cause mortality in persons with HIV
infection. Our findings are most relevant for epidemiologi-
cal studies of renal function in HIV-infected persons.
Studies of the general population and HIV-positive
persons have typically compared the MDRD and CKD-EPI
equations, and found the CKD-EPI equation to be closer
to the gold standard [7–10,15–17,29]. In the absence of a
gold standard in this and the majority of epidemiological
studies in HIV-infected populations, the predictive ability
of the two formulae for key clinical outcomes, such as
ESRD or mortality, should be an important consideration.
The two formulae predict these clinical outcomes equally
from a statistical perspective in this study, but without
gold standard GFR measurements, they may be predicting
equally well or equally badly. Discordance between CG and
CKD-EPI was much higher in our population when CG was
not standardized for BSA. All the measures of agreement
were considerably lower when CG was not standardized
for BSA, including kappa, correlation coefficients and the
proportion where the classification of normal, mildly
decreased, moderately decreased and severely decreased
was the same. In our population, CKD-EPI eGFRs tended to
be slightly higher than CG eGFRs when adjusted for BSA,
and lower than CKD-EPI eGFRs when not adjusted, sug-
gesting that the population is larger than the standard
assumed.
A recent review of non-HIV-positive persons comparing
MDRD with CKD-EPI in studies with a reference method
suggested that neither MDRD nor CKD-EPI was optimal
Fig. 2 Moderate and advanced chronic kidney disease (CKD) as predictors of fatal and nonfatal end-stage renal disease (ESRD) and mortality.
Moderate (Mod.) CKD [confirmed (> 3 months apart) estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2] and advanced (Adv.) CKD
(confirmed eGFR < 30 mL/min/1.73 m2) are included as time-updated variables. *Multivariate models adjusted for gender, race, ethnic origin, region,
CD4 count nadir and baseline date as fixed baseline covariates and hepatitis B, hepatitis C, prior AIDS diagnosis, prior non-AIDS-related event
(pancreatitis, malignancy and end-stage liver disease for ESRD (and additionally ESRD for mortality), cardiovascular event, diabetes, hypertension,
smoking status, anaemia, starting combination antiretroviral therapy, CD4 count, viral load and age as time-updated variables. BSA, body surface
area; CG, Cockcroft−Gault; CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
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across all populations and eGFR values [30]. The studies
comparing CG and CKD-EPI (or MDRD) equations for
estimating GFR are primarily confined to highly selected,
small, predominantly HIV-negative populations, with con-
flicting results [12,13,31–33]. In HIV-negative persons, less
discordance between CG and CKD-EPI or MDRD was found
in older persons and those of non-White race [5,34]. Some
epidemiological studies in HIV infection without access to
gold-standard eGFRs may use CG more frequently as the
formula does not incorporate race, which may be missing
or prohibited for use in analysis in a number of European
cohorts, while CKD-EPI may be the formula of choice for
cohorts without routine height or weight measurements.
Our results show that the formulae are closely correlated
and predict CKD and clinical outcomes equally.
It was reassuring that the predictors of moderate CKD
were similar regardless of which formula was used, and
these predictors have previously been reported in our
population [27]. In the absence of a gold standard, the
incidence of moderate CKD, defined as confirmed eGFR
< 60 mL/min/1.73 m2 [35], varied depending on the
formula used, but was higher using CG compared with
CKD-EPI, although the incidences of advanced CKD were
similar. This raises issues about person management and
resources, and about comparing the incidences of moderate
CKD across HIV-positive populations, where there is often
considerable heterogeneity in included persons as well as
different eGFR formulae used. Ideally, GFR should be
directly measured based on the clearance of infused inulin,
iohexol, or radiolabelled tracers.
eGFR is measured in the clinical setting for a variety of
reasons, including ensuring correct dosage of medications,
to monitor changes in eGFR over time, and to assess the
risk and development of other complications of progressive
renal dysfunction such as bone disease, anaemia and
hypertension [36]. The use of eGFRs as a surrogate marker
for renal function and predictor of clinical events relies on
the assumption that changes in eGFRs caused by interven-
tion translate into a change in the risk of ESRD or overall
mortality. To date, there is a shortage of data for HIV-
positive persons that show that changes in eGFR, however
measured, translate into reductions in clinically relevant
outcomes [37]. We fitted a variety of models, including
eGFR values, moderate and advanced CKD, and in all of
these the CG eGFR was as good at predicting clinical
outcomes as the CKD-EPI eGFR, as measured by the Akaike
information criterion.
The limitations of this study should be noted. Our results
are most useful for comparisons and interpretation of
epidemiological data and not for clinical decision making.
Many HIV-infected cohort studies do not routinely collect
height or weight, making use of CG impractical, while others
are prohibited from collecting information on race, which
is included in the CKD-EPI equation. Variation between
laboratories in serum creatinine measurements has been
well described [5,38], and the CKD-EPI equation requires
creatinine measured using enzymatic assays to allow its
accurate use. Unfortunately we have no information on the
assay used to determine creatinine in our individuals. We
have no data on cystatin C, also proposed as a useful mea-
sure of kidney function in some studies [39,40], or proteinu-
ria. Finally, it is worth noting that EuroSIDA is a cohort of
predominantly White individuals, limiting our power to
consider the influence of race, and the number of individ-
uals developing advanced CKD or ESRD was quite low.
In summary, there were modest differences in eGFRs In
HIV-positive persons when comparing CG adjusted for BSA
and CKD-EPI eGFR formulae. It would be reasonable to use
either formula in HIV-positive populations similar to those
in EuroSIDA. Although there were no gold-standard GFRs
available, predictors of CG- or CKD-EPI-defined moderate
CKD were similar and CG eGFRs performed as well as
CKD-EPI eGFRs in predicting two key clinical outcomes.
In the absence of a large study comparing eGFRs to a gold
standard, HIV-infected cohort studies can use either
formula, although sensitivity analyses should investigate
the robustness of the findings with both formulae, wher-
ever possible.
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